שווי כולל של החברה: Regulus Therapeutics (RGLS)

This daily price chart for Regulus Therapeutics (RGLS) on the GURU.Markets platform reflects an enterprise value of . Regulus Therapeutics relies on a staff of dedicated biochemists and FDA regulatory experts. The business is based on developing precision drugs for renal cysts with significant pricing power, as well as strategic partnerships with pharma behemoths to bring orphan disease treatments to market.

For the biotechnology business of Regulus Therapeutics (RGLS), which relies on outsourced oligonucleotide production, the valuation of all assets and liabilities is critical. The Enterprise Value (EV) metric combines market capitalization with net debt, determining the actual acquisition price of the company while accounting for its cash reserves. Analyzing this metric allows investors to filter out market noise and assess the fundamental cost of capital during periods of asset revaluation.